Annual Press Conference...Carl Zeiss Group, 2011/12 Annual Press Conference 13 December 2012 Overall...

13 December 2012Carl Zeiss Group, 2011/12 Annual Press Conference

Dr. Michael Kaschke

President and CEO

Thomas Spitzenpfeil

Chief Financial Officer

Annual Press ConferenceStuttgart, Germany, 13 December 2012

13 December 2012Carl Zeiss Group, 2011/12 Annual Press Conference 2

Dr. Michael KaschkePresident and CEO

Thomas SpitzenpfeilChief Financial Officer


+4%

-188m euros

+2%

Change

23,426Employees

30 SEP 2012 30 SEP 2011*

420 608EBIT (Earnings before Interest and Taxes)

4,163 4,084Revenue

FY 2011/12 FY 2010/11*in EUR million

24,326

Fiscal year 2011/12 at a glance

-144m euros 250 394Earnings

*The previous year's figures were adjusted due both to the classification of the Security and Defense Systems strategic business unit as a discontinued operation (IFRS 5) and to the changed method of valuating provisions for pensions.


Revenue distribution

Globally successful – 88% generated outside Germany

4

EMEA

€1,398m+7%*

Americas€1,056m+3%*

APAC€810m+10%*

Collaborations€899m-20%

*Adjusted for currency influences/calculated on a like-for-like basis.


Semiconductor Manufacturing Technology business group

Expected cyclical decline

2009/10

1,040

• High development expenditure for EUV affects earnings

• EUV milestone: first complete module delivered to ASML

• EUV will be the driver for significant energy savings

• Number of employees increased by 22% despite decline in revenue

• Prior year's figures like-for-like excluding electron microscopy

+

2010/11

1,181

2011/12

Revenue

€967 million-18%

+

+

5

-


Industrial Metrology business group

Dynamic growth at high level

2009/10

292 • Customers positive about broad product portfolio

• Market share gained through global system solutions

• Third production site outside Germany after USA and China opened in Bangalore, India

• Number of employees increased by 12%

+

+

2010/11

394

2011/12

Revenue

€495 million+26%

+

+

6


Microscopy business group

Position in difficult environment maintained

2009/10

544

• BioScience – research feeling noticeable budget cuts

• Materials microscopy performing extraordinarily well

• Correlative microscopy accepted by customers


• Prior year's figures like-for-like including electron microscopy

+

-

2010/11

620

2011/12

Revenue

€650 million+5%

+

+

7


Medical Technology business group

Sustained dynamic development with strong growth in Asia

2009/10

754

• Growth considerably outpaced market in all areas

• Focus on Asia – on-site development for middle market segment

• 100 Years of Medical Technology


+

+

2010/11

854

2011/12

Revenue

€984 million+15%

+

+

8

The values deviate from the published figures of Carl Zeiss Meditec AG as a result of different consolidation models.


Vision Care business group

Restructuring after 100% acquisition taking hold

2009/10

886

• Winner in patent dispute about freeform technology; multi-year licensing agreement with competitors

• Production and sales network optimized around the world

• Number of employees decreased by 4%2010/11

849

2011/12

Revenue

€860 million+1%

+

+

-

9


2009/10

135

• Camera Lenses with innovation fireworks at 2012 photokina

• Good growth in Sports Optics

• Planetariums open up new markets, including Sri Lanka

• Number of employees unchanged

+

+

2010/11

160

2011/12

Revenue

€178 million+11%

+

+

10

Camera Lens, Sports Optics, Planetariums strategic business units

Opportunities with innovations on growth markets used


Additional financial highlights for 2011/12


Investments in property, plant and equipment

Investment amount almost doubled

2009/10

53

2010/11*

119

2011/12

€289 million+€129 million

12

Investments in property, plant and equipment

Depreciation of property, plant and equipment

96

160

135



Building for the future: look at current projects (Germany)

Expansion of office space for Semiconductor Manufacturing Technology, featuring new company restaurant

Construction of a cogeneration unit, Oberkochen

New construction of logistics center,Oberkochen-Königsbronn

New construction of a development, administrative and production facility for Medical Technology


Building for the future: look at current projects (outside Germany)

14

Campus in Bangalore, India Rooftop solar panels in Dublin, California


Investments in research and development

9% of revenues for record investments

2009/10

291

2010/11*

343

2011/12

€390 million+14%

15



Economic Value Added

Goal achieved; triple-digit increase in corporate value

16

€134 millionIncreased EVA despite higher investments


Free cash flow

Cash flow characterized by positive EBIT and high investments

2009/10*

571

2010/11*

622

2011/12

€332 million-€290 million

17



Financial strength

Strong cash flows for record investments without loss of substance

1 OCT 2010* 30 SEP 2011

847

30 SEP 2010

€373 million-6%

18

Gross cash

Net cash

1337

762

71

397

*From this date full consolidation of Carl Zeiss Vision.


Equity

26% equity ratio despite increasing pension provisions

30 SEP 2010*

1,150

30 SEP 2011*

1,164

30 SEP 2010

€1,213 million+4%

19

.*The previous year's figures were adjusted due both to the classification of the Security and Defense Systems strategic business unit as a discontinued operation (IFRS 5) and to the changed method of valuating provisions for pensions.


Forecast for the business groups

Semiconductor Manufacturing TechnologyFurther downward trend in the market for semiconductor equipment, recovery dependent on consumer behavior in PC segment

Industrial MetrologyDynamic growth of the past two years will slow – still potential in new markets

MicroscopyNational debt crisis impacts government spending – focus on rapidly developing economies and industrial materials microscopy

Medical TechnologyDemographic trend creates good environment for further growth – but partially declining healthcare expenditure in developing markets

Vision CareContinuation of course of growth in established markets – focused activities in dynamic economies

20


Overall forecast for 2012/13

21

Good foundationOrder backlog of around 4.2 billion euros – Carl Zeiss is a very healthy company

Ambitious goals in a difficult environmentRevenue of around 4 billion euros – Carl Zeiss is unwavering in its pursuit of investment course and Agenda 2016

Strong portfolio ensures balanceSignals from most business groups remain positive


Contact

If you have any questions, please do not hesitate to contactJörg NitschkeCorporate CommunicationsPhone +49 (0) 7364/ 20-3242Email: [email protected]

Annual Press Conference...Carl Zeiss Group, 2011/12 Annual Press Conference 13 December 2012 Overall...

Documents

Transcript of Annual Press Conference...Carl Zeiss Group, 2011/12 Annual Press Conference 13 December 2012 Overall...